Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Clinical and Molecular Characteristics of X-Linked Agammaglobulinemia Patients 55 Years or Older.
Journal: The journal of allergy and clinical immunology. In practice
Published: April 01, 2025
Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.
Journal: Journal of clinical immunology
Published: March 16, 2023
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies.
Journal: Frontiers in immunology
Published: November 28, 2022
Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
Journal: Expert review of clinical immunology
Published: November 08, 2022
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
Journal: Clinical and experimental immunology
Published: June 22, 2022
Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: May 20, 2022
An Updated Survey of SCID Outcomes Without Preconditioning Chemotherapy.
Journal: The journal of allergy and clinical immunology. In practice
Published: January 20, 2022
Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
Journal: Immunotherapy
Published: January 06, 2022
Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome.
Journal: Journal of child and adolescent psychopharmacology
Published: February 19, 2021
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Journal: Frontiers in immunology
Published: October 18, 2018
Last Updated: 09/26/2026